Estimating cure proportion in cancer clinical trials using flexible parametric cure models
The study analyzed CheckMate 141 trial data to estimate cure proportions in patients treated with nivolumab for recurrent squamous cell carcinoma of the head and neck, using a Flexible Parametric Cure Model (FPCM) with varying knot numbers and placements. The FPCM, compared to the Kaplan-Meier (KM) method and Weibull Non-Mixture Cure Model (WNCM), showed significant impact of knot placement on cure proportion estimates. A simulation study was conducted to determine optimal knot placement for accurate cure proportion estimation.
Reference News
The study analyzed CheckMate 141 trial data to estimate cure proportions in patients treated with nivolumab for recurrent squamous cell carcinoma of the head and neck, using a Flexible Parametric Cure Model (FPCM) with varying knot numbers and placements. The FPCM, compared to the Kaplan-Meier (KM) method and Weibull Non-Mixture Cure Model (WNCM), showed significant impact of knot placement on cure proportion estimates. A simulation study was conducted to determine optimal knot placement for accurate cure proportion estimation.